| Literature DB >> 29026535 |
Xia Zheng1, Jian-Feng Wang2, Wang-Lan Xu3, Jun Xu1, Juan Hu1.
Abstract
BACKGROUND: To analyze the clinical characteristics and outcomes of carbapenem-resistant Klebsiella pneumoniae (CRKp) and carbapenem-susceptible K. pneumoniae (CSKp) bloodstream infections (BSIs), and to study the risk factors for development of CRKp BSI and K. pneumoniae BSI-related mortality.Entities:
Year: 2017 PMID: 29026535 PMCID: PMC5625719 DOI: 10.1186/s13756-017-0256-2
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Clinical symptoms of K. pneumoniae BSI
| Variable | CSKp ( | CRKp ( |
|
|---|---|---|---|
| APACHEII score(mean ± SD) | 18.18 ± 7.48 | 15.03 ± 6.38 | 0.089 |
| WBC 10E9/L (mean ± SD) | 14.24 ± 13.63 | 13.99 ± 9.66 | 0.497 |
| leukocytes count (mean ± SD) | 81.20 ± 14.60 | 88.02 ± 7.95 | 0.180 |
| CRP(mg/l)(mean ± SD) | 162.49 ± 118.07 | 113.74 ± 79.63 | 0.191 |
| ALT (mean ± SD) | 152.88 ± 399.23 | 49.84 ± 50.05 | 0.359 |
| AST (mean ± SD) | 490.82 ± 1655.64 | 49.63 ± 48.54 | 0.088 |
| Total bilirubin (mean ± SD) | 73.06 ± 142.17 | 62.68 ± 128.66 | 0.754 |
| Direct bilirubin (mean ± SD) | 43.29 ± 83.58 | 39.48 ± 86.63 | 0.779 |
| PT (s) (mean ± SD) | 17.71 ± 10.54 | 15.05 ± 5.27 | 0.439 |
| Creatinine (mean ± SD) | 165.06 ± 127.01 | 93.77 ± 84.35 | 0.039 |
| Urea nitrogen (mean ± SD) | 14.42 ± 9.88 | 14.40 ± 10.05 | 0.931 |
Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, WBC white blood cell, CRP C-reactive protein, ALT alanine transaminase, AST aspartate transaminase, PT prothrombin time
Clinical outcomes of K. pneumoniae BSI
| Variable | CSKp (n = 17) | CRKp ( |
|
|---|---|---|---|
| Duration of mechanical ventilation (mean ± SD)(d) | 18.50 ± 31.91 | 28.72 ± 31.06 | 0.127 |
| Current ICU stay | 21.47 ± 33.67 | 31.74 ± 30.75 | 0.073 |
| Bacterial clearance rate | 6(35%) | 10(32%) | 0.718 |
| 7-day survival rate | 11(65%) | 23(74%) | 0.489 |
| 14-day survival rate | 10(59%) | 21(68%) | 0.537 |
| 28-day survival rate | 8(47%) | 19(61%) | 0.342 |
Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, ICU intensive care unit
Univariate analysis of risk factors for CRKp BSI
| Variable | CSKp (n = 17) | CRKp (n = 31) | Univariate analysis | ||
|---|---|---|---|---|---|
| Adjusted OR | 95% CI |
| |||
| Sex (male, n) | 11(65%) | 27(87%) | 0.611 | 0.144—2.596 | 0.502 |
| Age (y) (mean ± SD) | 62.71 ± 16.34 | 57.61 ± 14.78 | 0.306 | ||
| Co- morbidities | |||||
| Diabetes mellitus | 5 (29%) | 9 (29%) | 0.982 | 0.268—3.602 | 0.978 |
| Hypertension | 9 (53%) | 15 (48%) | 0.833 | 0.255—2.724 | 0.763 |
| Coronary heart disease | 1 (6%) | 3 (10%) | 1.714 | 0.164—17.886 | 1 |
| Chronic liver disease | 3(18%) | 6(19%) | 1.120 | 0.242–5.186 | 1 |
| Chronic renal failure | 2 (12%) | 4 (13%) | 1.111 | 0.182—6.796 | 0.909 |
| Solid organ tumor | 4 (24%) | 7 (23%) | 0.948 | 0.233—3.850 | 0.940 |
| HIV | 0 | 0 | NA | NA | NA |
| Surgery in the past medical historya | 3 (18%) | 5 (16%) | 0.897 | 0.186—4.322 | 0.893 |
| Prior healthcare-associated exposure | 7 (41%) | 9 (29%) | 0.584 | 0.169—2.017 | 0.393 |
| Prior medicine exposure | |||||
| Glucocorticoid | 7 (41%) | 13 (42%) | 1.032 | 0.311—3.428 | 0.959 |
| Immunosuppressorb | 1 (6%) | 2 (6%) | 1.103 | 0.093—13.135 | 1 |
| Prior use of antimicrobials | |||||
| Penicillin | 3 (18%) | 10 (32%) | 2.105 | 0.480—9.237 | 0.318 |
| Second cephalosporin | 1 (6%) | 4 (13%) | 2.240 | 0.228—22.051 | 0.838 |
| extended-spectrum cephalosporins | 7 (41%) | 15 (48%) | 1.224 | 0.351—4.269 | 0.750 |
| Aminoglycosides | 1 (6%) | 3 (10%) | 1.615 | 0.153—17.016 | 1 |
| Quinolones | 1 (6%) | 3 (10%) | 1.615 | 0.153—17.016 | 1 |
| Tigecycline | 0 | 4 (13%) | 0.625 | 0.492—0.795 | 0.613 |
| Imipenem | 1 (6%) | 11(39%) | 8.556 | 0.984—74.408 |
|
| Meropenem | 1 (6%) | 12 (39%) | 9.882 | 1.141—85.619 |
|
| Ertapenem | 0 | 0 | NA | NA | NA |
| Linezolid | 1 (6%) | 12 (39%) | 9.882 | 1.141—85.619 |
|
| Glycopeptides Vancomycin | 1 (6%) | 8 (26%) | 5.333 | 0.599—47.468 | 0.216 |
| Teicoplanin | 1 (6%) | 5 (16%) | 2.917 | 0.309—27.560 | 0.333 |
| Invasive procedure before | |||||
| Central venous catheterization | 10(59%) | 30 (97%) | 21.000 | 2.294—192.225 |
|
| Trachea cannula | 4(24%) | 10 (32%) | 1.548 | 0.401—5.971 | 0.525 |
| Tracheotomy | 5(29%) | 12 (39%) | 1.516 | 0.426—5.393 | 0.519 |
| Urinary catheter | 7(41%) | 23 (74%) | 4.107 | 1.168—14.436 |
|
| stomach tube | 14(82%) | 27 (87%) | 1.446 | 0.283—7.384 | 0.656 |
| Intrathoracic drain | 0(0) | 4 (13%) | 0.614 | 0.485—0.776 | 0.282 |
| Abdominal cavity drainage-tube | 5(29%) | 15 (48%) | 2.250 | 0.639—7.923 | 0.202 |
| External ventricular drainage tube care | 0(0) | 1 (3%) | 0.612 | 0.490—0.765 | 1 |
| Liver function on admission | 5(35%) | 3 (10%) | 0.257 | 0.053—1.252 |
|
| Renal function on admission | 7(41%) | 4(13%) | 0.275 | 0.071—1.070 |
|
| APACHE II score on admission | 12.29 ± 7.32 | 9.45 ± 4.60 | 0.334 | ||
Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae, OR odds ratio, CI confidence interval, HIV human immunodeficiency virus, APACHE Acute Physiology and Chronic Health Evaluation
aHistory of surgery and non-invasive procedures, such as endoscopy or colonoscopy, are excluded from this category
bImmunosuppressors: Immunosuppressive drugs, immunosuppressive agents or antirejection medications are drugs that inhibit or prevent activity of the immune system, including cytostatics, antibodies, drugs acting on immunophilins, etc. (https://en.wikipedia.org/wiki/Immunosuppressive_drug)
Multivariate analysis of risk factors for CRKp BSI
| Variable | Adjusted OR | 95% CI |
|
|---|---|---|---|
| Indwelling central venous catheters | 14.343 | 1.063—193.444 | 0.045 |
| Exposure to meropenem | 11.968 | 0.756—69.720 | 0.086 |
| Exposure to imipenem | 7.258 | 0.945—151.497 | 0.055 |
Abbreviations: OR odds ratio, CI confidence interval
Univariate analysis of the 28-day mortality rate of K. pneumoniae BSI patients in the ICU
| Variable | Died ( | Survived ( | Univariate analysis | ||
|---|---|---|---|---|---|
|
| OR | 95% CI | |||
| Sex (male, n) | |||||
| Age (y) (mean ± SD) | 57.74 ± 16.63 | 61.57 ± 13.69 | 0.448 | ||
| APACHE II score at admission | 11.50 ± 5.53 | 10.07 ± 4.95 | 0.406 | ||
| APACHE II score on the day of bacteremia | 18.29 ± 7.36 | 14.48 ± 6.11 | 0.031 | ||
| Liver failurea at admission | 7 | 8 | 0.784 | 1.188 | 0.348—4.051 |
| Kidney failureb at Admission | 4 | 7 | 0.574 | 0.672 | 0.168—2.694 |
| Liver failure on the day of bacteremia | 11 | 7 | 0.06 | 3.143 | 0.933—10.584 |
| Kidney failure on the day of bacteremia | 6 | 6 | 0.614 | 1.400 | 0.377—5.195 |
| Co-infection | 14 | 20 | 0.575 | 0.700 | 0.2—2.445 |
| CRKp | 12(57.1%) | 19(70.3%) | 0.342 | 0.561 | 0.170—1.856 |
| Diabetes mellitus | 5(23.8%) | 9(23.3%) | 0.371 | 0.556 | 0.152—2.027 |
| Hypertension | 10(47.6%) | 14(51.9%) | 0.771 | 0.844 | 0.270—2.644 |
| Coronary heart disease | 2(9.5%) | 2(7.4%) | 0.792 | 1.316 | 0.170—10.208 |
| Chronic renal failure | 2(9.5%) | 4(14.8%) | 0.582 | 0.605 | 0.1—3.672 |
| Solid organ tumor | 4(19%) | 7(25.9%) | 0.574 | 0.672 | 0.168—2.694 |
| Surgery in the past medical history | 2(9.5%) | 6(22.2%) | 0.242 | 0.368 | 0.066—2.050 |
| Prior healthcare-associated exposure | 8(38.1%) | 8(29.6%) | 0.537 | 1.462 | 0.437—4.889 |
| Glucocorticoid | 8 | 12 | 0.658 | 0.769 | 0.240—2.460 |
| Immunosuppressor | 2(9.5%) | 1(3.7%) | 0.409 | 2.737 | 0.231—32.430 |
| Central venous catheterization | 17(81%) | 23(85.2%) | 0.696 | 0.739 | 0.161—3.383 |
| Trachea cannula | 9(42.9%) | 5(18.5%) | 0.066 | 3.3 | 0.899—12.108 |
| Tracheotomy | 6(27.3%) | 11(40.7%) | 0.325 | 0.545 | 0.162—1.833 |
| Urinary catheter | 13(61.9%) | 17(16.9%) | 0.940 | 0.956 | 0.295—3.102 |
| Abdominal cavity drainage- tube | 6(28.6%) | 14(51.9%) | 0.105 | 0.371 | 0.111—1.247 |
| Stomach tube | 18(85.7%) | 23(85.2%) | 0.959 | 1.043 | 0.305—0.593 |
| Intrathoracic drain | 0 | 4(14.8%) | 0.121 | 0.523 | 0.394—0.693 |
| External ventricular drainage tube care | 1(4.7%) | 0 | 0.438 | 0.426 | 0.305—0.593 |
Abbreviations: OR odds ratio, CI confidence interval, CRKp carbapenem-resistant Klebsiella pneumoniae
aLiver failure was defined as a serum bilirubin level of >3 mg/dl and/or prothrombin time (PT) of <50% on day 5 after surgery or thereafter; in patients with jaundice, it was defined as an increase in the serum bilirubin level or a PT < 50% on day 5 or thereafter [53]
bKidney failure was defined as a creatinine level of ≥2 mg/dl or requirement for dialysis [33]
Fig. 1Pulsed-field gel electrophoresis (PFGE) results. Pulsotypes of 33 K. pneumoniae blood isolates. The PFGE patterns revealed that the 33 isolates had different origins
Fig. 2Multilocus sequence typing (MLST) results. Eighteen sequence types (STs) of 33 K. pneumoniae blood isolates. MLST indicated considerable clonal diversity; 18 STs were detected, of which ST11 comprised the majority
Frequency rates of bacterial virulence genes in 33 isolates
| Variable | CSKp ( | CRKp (n = 21) | P |
|---|---|---|---|
| rmpA2 | 3 | 4 | 0.686 |
| Alls | 3 | 0 | 0.04 |
| K1 | 1 | 0 | 0.364 |
| K5 | 0 | 1 | 1 |
| magA | 4 | 1 | 0.047 |
| K1+ magA | 1 | 0 | 0.364 |
| rmpA2 + magA | 1 | 0 | 0.364 |
| alls + magA | 1 | 0 | 0.364 |
| rmpA | 0 | 0 | – |
| K2 | 0 | 0 | – |
| K20 | 0 | 0 | – |
| K54 | 0 | 0 | – |
| K57 | 0 | 0 | – |
Abbreviations: CSKp carbapenem-susceptible Klebsiella pneumoniae, CRKp carbapenem-resistant Klebsiella pneumoniae